July 25 Apricus Biosciences * Apricus biosciences inc says apricus and sandoz agree to mutually terminate license agreement * Apricus eligible to receive additional $3.6 million in upfront and pre-commercialization milestone payments for ... Reuters UK, 4 days ago
Apricus, Sandoz To Terminate License For Vitaros; Expands Tie-up With Ferring - Quotenet.com, 4 days ago
Apricus Biosciences Further Expands Existing Vitaros Partnership with Ferring Pharmaceuticals in Europe and Asia [Palestine Chronicle, The] - Pharmacy Choice, 3 days ago
3 images for "sandoz inc"
By Razak Musah Baba LONDON--AstraZeneca PLC (AZN.LN) has entered an agreement with Sandoz, Inc. and affiliates to resolve a U.S. patent litigation relating to its hormonal therapy drug Faslodex, the British pharmaceutical giant said Wednesday. ...Morningstar.com, 2 weeks ago AstraZeneca Enters Into Deal To Resolve Faslodex Patent Litigation In US Pharmacy Choice, 2 weeks ago ASTRAZENECA : Resolves Faslodex Patent Litigation in US 4 Traders, 2 weeks ago ASTRAZENECA : AZ resolves Faslodex patent litigation in the US 4 Traders, 2 weeks ago
The Federal Circuit answered one of the questions left open by its July 27, 2015, decision in Amgen Inc. v. Sandoz Inc. (Appeal No. 2015-1499): whether the 180-day commercial marketing notice under the Biologics Price Competition and Innovation Act ...JD Supra, 3 weeks ago New Guidance on Mandatory Notice in the Biosimilar Patent Dance JD Supra, 2 weeks ago Biosimilars: 180-day notice is mandatory Intellectual Asset Management, 2 weeks ago Federal Circuit Rules Biosimilar Notice of Commercial Marketing Mandatory National Law Review, 3 weeks ago
Amgen, Inc. ( NASDAQ:AMGN ) is slated to report its second quarter earnings today after markets close. Analysts expect only a slight yearly increase in revenue, as generic competition has taken its toll on some of its blockbuster drugs. What ...Bidness Etc, 1 day ago AbbVie Inc: FDA May Favor Early Entry for Humira Biosimilar Bidness Etc, 2 weeks ago Amgen, Inc. Poses Real Threat to AbbVie Inc Humira Bidness Etc, 2 weeks ago Stiff Biosimilar Headwinds To Negatively Impact Amgen's Aging Drug Portfolio Benzinga.com, 1 month ago
Jul.28.16 | About: Versartis, Inc. (VSAR) Follow Registered investment advisor, hedge fund manager, research analyst, biotech | Summary Versartis, Inc. (NASDAQ: VSAR) is developing a long-acting (once or twice monthly) formulation of ...Seeking Alpha, 1 day ago
AbbVie Inc. ( NYSE:ABBV ) won yet another label expansion for its anti-inflammatory megablockbuster drug Humira in the US on Friday. The drug can now be used for the treatment of non-infectious intermediate, posterior and panuveitis in adults. This ...Bidness Etc, 3 weeks ago AbbVie Inc Pipeline May Not Compensate for Humira's Loss Bidness Etc, 1 month ago Abbvie: Home Cooking Is Hard To Beat Seeking Alpha, 4 weeks ago
June 9 Spectrum Pharmaceuticals Inc : * On June 8, 2016, co's unit , Allos Therapeutics and Sandoz Inc entered into a settlement agreement * Spectrum Pharmaceuticals Inc says settlement agreement to resolve patent litigation relating to ...Reuters UK, 1 month ago Spectrum Pharmaceuticals' unit, Allos Therapeutics and Sandoz enter settlement agreement Reuters UK, 1 month ago
- Hispanica International Delights of America, Inc. (OTC PINK: HISP), a diversified food and beverage company in the Hispanic and ethnic food industry, announced today the appointment of Bassam Damaj, PhD to its Board of Directors. Dr. Damaj brings ...4 Traders, 2 weeks ago
Novartis AG's cheaper version of Amgen Inc's arthritis drug Enbrel is highly similar in potency and safety to the original and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday. The panel voted ...Pharmaceutical Tech.com, 2 weeks ago FDA: Novartis Arthritis Drug 'Highly Similar' to Amgen's Enbrel Pharmaceutical Manufacturing Magazine, 2 weeks ago Novartis copy of Amgen arthritis drug highly similar: FDA staff Pharma Focus Asia, 2 weeks ago U.S. FDA panel supports Novartis version of Amgen arthritis drug Sharenet, 2 weeks ago
Amgen Inc. AMGN announced an exclusive agreement with Daiichi Sankyo Company, Limited for the commercialization of nine biosimilars in Japan including biosimilars of AbbVie's ABBV Humira and Roche Holding AG's RHHBY Avastin and Herceptin. The ...Yahoo! Singapore, 2 weeks ago
More from: , Zacks.com...and 2 other sources
on your WebpageAdd Widget >Get your members hooked!